This Overlooked Gut Microbe May Team Up With Bacteria to Worsen Ulcerative Colitis

Most people have heard of gut bacteria. Far fewer have heard of gut archaea, a completely separate domain of single celled life that also calls the human digestive tract home. A newly posted study has now built the largest genome catalog of these microbes to date, and buried in that catalog is a finding that could matter for anyone living with ulcerative colitis: one archaeon appears to be teaming up with a specific gut bacterium in a pattern that shows up only in inflamed guts, not healthy ones.

Key takeaways

• Researchers assembled a genome catalog of 2,096 archaea recovered from the human gut, spanning 93 species, including 44 species never previously grown or characterized in a lab.
• Across 7,294 samples covering 33 different diseases, archaeal diversity rose in some conditions, including Parkinson's disease, and fell in others, including autoimmune and gastrointestinal diseases.
• In ulcerative colitis specifically, one archaeon showed a new, positive correlation with a gut bacterium that was absent in healthy guts, a possible microbial "alliance" that may amplify inflammation. The work is a preprint and the disease links are correlational, not proof of cause and effect.

New Genome Catalog Maps the Human Gut's Overlooked Archaea

A team of researchers has assembled a genome catalog of 2,096 archaea (a distinct domain of single celled microbes, separate from both bacteria and human cells) recovered from the human gut. Mining 11,818 previously collected gut metagenomes (the pooled genetic material sequenced directly from a stool sample), they identified 93 distinct archaeal species, 44 of which had never before been grown or genetically characterized. This effort roughly doubles the size of the most recent major reference, a 2022 Nature Microbiology catalog that described 1,167 gut archaeal genomes, reflecting how quickly this corner of the microbiome is being mapped. Geography, more than any single disease, turned out to be the strongest driver of which archaeal species showed up in a person's gut, underscoring how much regional diet and environment shape this understudied part of the microbiome, a domain of life some researchers have called an underappreciated piece of human microbial health.

Archaeal Diversity Shifts Across 33 Different Diseases

The researchers then cross referenced archaeal genetic diversity against 7,294 stool samples spanning 33 different diseases. Diversity was higher than average in people with Parkinson's disease, polycystic ovary syndrome (PCOS, a hormonal condition), and atrial fibrillation (an irregular heart rhythm), while it was lower in people with various autoimmune conditions and gastrointestinal diseases, including inflammatory bowel disease (IBD). That last category is where the study's most specific finding lives: among 1,244 IBD related samples, people with ulcerative colitis (a form of IBD that inflames the lining of the colon) showed a distinct pattern involving one particular archaeon.

Tracing an Archaea-Bacteria Alliance in Ulcerative Colitis

That archaeon, identified in the catalog as Methanocatella smithii_A (a close relative of the well known gut archaeon Methanobrevibacter smithii), formed a newly detected positive correlation with the bacterium Bacteroides fragilis specifically in the guts of ulcerative colitis patients. Critically, this pairing was not detected in the healthy control samples, only in inflamed guts. The researchers describe this as a possible cross feeding relationship (where one microbe's byproducts feed another) that could function as a kind of microbial alliance, potentially amplifying gut inflammation in ulcerative colitis. The idea that non-bacterial microbes shape IBD is not entirely new. A prior review of the gut's non-bacterial residents in IBD had already flagged archaea, viruses and fungi as an underexplored piece of the inflammatory bowel disease puzzle, though this new preprint is among the first to name a specific archaeon-bacterium pair tied to ulcerative colitis.

What an Archaea-Bacteria Pairing Could Mean for IBD Patients

For someone managing ulcerative colitis, this finding does not change anything about current treatment, and no one should read it as evidence that a probiotic, supplement, or dietary change targeting archaea is proven to help. What it does offer is a new candidate to study: if this archaeon-bacterium pairing really does worsen inflammation, it could eventually become a marker doctors check for, or even a target for future therapies designed to break up that microbial partnership. For now, it is a lead worth watching rather than something to act on, and it is a reasonable thing to mention to a gastroenterologist as an example of ongoing microbiome research relevant to IBD, without expecting it to change a current treatment plan.

This Is a Preprint Built on Correlational Evidence

Several caveats matter here. First, this is a preprint, meaning it has not yet gone through formal peer review, and its conclusions could shift during that process. Second, 96.99 percent of the genomes in the catalog are metagenome assembled genomes (MAGs), reconstructed computationally from mixed community sequencing data rather than grown and sequenced individually in a lab, a method that can sometimes miss or misassemble parts of an organism's genome. Third, and most importantly, the disease associations here, including the ulcerative colitis finding, come from network and differential abundance analyses (statistical methods for spotting patterns across large datasets), not from experiments that directly tested whether the archaeon and bacterium cause more inflammation together. Correlation is not causation, and that gap has not been closed yet.

What Comes Next for Gut Archaea Research

The logical next step is peer review, followed by laboratory experiments that actually test whether Methanocatella smithii_A and Bacteroides fragilis interacting together changes inflammation in a model system, rather than just co-occurring in the same inflamed guts. Given how many other diseases showed shifts in archaeal diversity in this same dataset, from Parkinson's disease to PCOS, this catalog is likely to seed a wave of follow-up studies well beyond inflammatory bowel disease.

Common Questions

What are archaea, and how are they different from gut bacteria? Archaea are a separate domain of single celled life from bacteria, even though both are microscopic and both live in the gut. The best known gut archaeon, Methanobrevibacter smithii, helps break down fermentation byproducts from fiber digestion; the newly cataloged relative involved in this study, Methanocatella smithii_A, appears to have its own specific relationships with gut bacteria.

Does this mean gut archaea cause ulcerative colitis? No. The study found a correlation between one archaeon and one bacterium that shows up specifically in ulcerative colitis guts, not proof that this pairing causes the disease or its flares.

Is this study peer reviewed? No. It is currently a preprint, meaning it has been shared publicly before undergoing formal peer review, so its findings should be treated as preliminary until that process is complete.

References

1. Qiulong Yan, Changming Chen, Wei Yang, et al. (2026). A genome catalog reveals the global landscape of the human gut archaeome and its relevance to inflammatory bowel disease. https://doi.org/10.21203/rs.3.rs-10112203/v1
2. Cynthia Maria Chibani, Alexander Mahnert, Guillaume Borrel, et al. (2022). Publisher Correction: A catalogue of 1,167 genomes from the human gut archaeome. Nature Microbiology. https://doi.org/10.1038/s41564-022-01061-8
3. Patricia Geesink, Thijs J. G. Ettema (2021). The human archaeome in focus. Nature Microbiology. https://doi.org/10.1038/s41564-021-01031-6